一个无信息价值的真相：阿玛林公司药品未贴标签推广的逻辑
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
作者信息
Hey Spencer Phillips, Kesselheim Aaron S
机构信息
The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
The Harvard Center for Bioethics, Harvard Medical School, Boston, Massachusetts, United States of America.
出版信息
PLoS Med. 2016 Mar 15;13(3):e1001978. doi: 10.1371/journal.pmed.1001978. eCollection 2016 Mar.
Abstract
Spencer Phillips Hey and Aaron Kesselheim propose that informativeness-asserting scientific facts-rather than truthfulness ought to be the standard for regulating commercial speech about pharmaceuticals.
摘要
斯宾塞·菲利普斯·黑伊和亚伦·凯塞尔海姆提出，对于规范有关药品的商业言论而言，应当以提供信息——陈述科学事实——而非真实性作为标准。
相似文献
1
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.一个无信息价值的真相：阿玛林公司药品未贴标签推广的逻辑
PLoS Med. 2016 Mar 15;13(3):e1001978. doi: 10.1371/journal.pmed.1001978. eCollection 2016 Mar.
2
Free Speech and Pharmaceutical Regulation -- Fishy Business.言论自由与药品监管——可疑之事。
JAMA Intern Med. 2016 Mar;176(3):295-6. doi: 10.1001/jamainternmed.2015.8155.
3
Assessing the clinical benefits of lipid-disorder drugs.评估脂质紊乱药物的临床益处。
N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866.
4
The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.21世纪的医疗产品推广：药品未注册用法营销与第一修正案相关问题
JAMA. 2015 Nov 3;314(17):1795-6. doi: 10.1001/jama.2015.12045.
5
Regulating Off-Label Promotion - A Critical Test.规范药品未标示用途推广——一项关键考验。
N Engl J Med. 2016 Dec 15;375(24):2313-2315. doi: 10.1056/NEJMp1611755. Epub 2016 Nov 2.
6
Off-label marketing and the First Amendment.药品未按批准适应症用药的营销与第一修正案
N Engl J Med. 2013 Jan 10;368(2):103-5. doi: 10.1056/NEJMp1214926. Epub 2012 Dec 12.
7
The limits of free speech.言论自由的界限。
Nature. 2012 Dec 20;492(7429):311. doi: 10.1038/492311a.
8
Pros and cons of off-label promotion investigations and prosecutions.药品未按批准说明书用药推广的调查与起诉的利弊
Food Drug Law J. 2006;61(3):577-83.
9
Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.提供证据背景以减轻因药品未按批准说明用药宣传导致医生误解的随机研究。
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e006073. doi: 10.1161/CIRCOUTCOMES.119.006073. Epub 2019 Nov 11.
10
Shifting terrain in the regulation of off-label promotion of pharmaceuticals.药品未标示用途推广监管方面不断变化的形势。
N Engl J Med. 2009 Apr 9;360(15):1557-66. doi: 10.1056/NEJMhle0807695.
本文引用的文献
1
Free Speech and Pharmaceutical Regulation -- Fishy Business.言论自由与药品监管——可疑之事。
JAMA Intern Med. 2016 Mar;176(3):295-6. doi: 10.1001/jamainternmed.2015.8155.
2
The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.21世纪的医疗产品推广：药品未注册用法营销与第一修正案相关问题
JAMA. 2015 Nov 3;314(17):1795-6. doi: 10.1001/jama.2015.12045.
3
Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes.生物标志物、风险因素与风险：澄清关于替代终点和临床结局的争议
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):457-9. doi: 10.1161/CIRCOUTCOMES.115.002245.
4
Forbidden and Permitted Statements about Medications--Loosening the Rules.关于药物的禁忌与许可声明——放宽规则
N Engl J Med. 2015 Sep 3;373(10):967-73. doi: 10.1056/NEJMhle1506365.
5
Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease.ω-3长链多不饱和脂肪酸在心血管疾病防治中的应用指征
Heart Lung Circ. 2015 Aug;24(8):769-79. doi: 10.1016/j.hlc.2015.03.020. Epub 2015 Apr 3.
6
Assessing the clinical benefits of lipid-disorder drugs.评估脂质紊乱药物的临床益处。
N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866.
7
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).脂蛋白与心血管事件的关系：AIM-HIGH 试验（代谢综合征伴低 HDL/高甘油三酯血症的动脉粥样硬化血栓形成干预及对全球健康结局的影响）。
J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.
8
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.HPS2-THRIVE 随机安慰剂对照试验纳入 25673 例 ER 烟酸/拉罗匹仑的高危患者：试验设计、预先指定的肌肉和肝脏结局以及停止研究治疗的原因。
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
9
Statins for the primary prevention of cardiovascular disease.他汀类药物用于心血管疾病的一级预防。
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004816. doi: 10.1002/14651858.CD004816.pub5.
10
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).依泽替米贝（AMR101）治疗他汀类药物治疗后持续性高甘油三酯血症患者的疗效和安全性（来自 ANCHOR 研究）。
Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.
Zotero 插件